Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Adenosine A1 Receptor Agonist 2-chloro-N6-cyclopentyladenosine and Hippocampal Excitability During Brain Development in Rats

P. Fabera, M. Parizkova, L. Uttl, K. Vondrakova, H. Kubova, G. Tsenov, P. Mares,

. 2019 ; 10 (-) : 656. [pub] 20190614

Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc19036003

Objective: The adenosinergic system may influence excitability in the brain. Endogenous and exogenous adenosine has anticonvulsant activity presumably by activating A1 receptors. Adenosine A1 receptor agonist 2-chloro-N6-cyclopentyladenosine (CCPA) may thus bolster anticonvulsant effects, but its action and the number of A1 receptors at different developmental stages are not known. Methods: Hippocampal epileptic afterdischarges (ADs) were elicited in 12-, 15-, 18-, 25-, 45-, and 60-day-old rats. Stimulation and recording electrodes were implanted into the dorsal hippocampus. The A1 receptor agonist 2-chloro-N6-cyclopentyladenosine (CCPA, 0.5 or 1 mg/kg) was administered intraperitoneally 10 min before the first stimulation. Control animals were injected with saline. All rats were stimulated with a 2-s series of 1-ms biphasic pulses delivered at 60 Hz with increasing stepwise intensity (0.05-0.6 mA). Each age and dose group contained 9-14 animals. The AD thresholds and durations were evaluated, and the A1 receptors were detected in the hippocampus in 7-, 10-, 12-, 15-, 18-, 21-, 25-, 32-, and 52-day-old rats. Results: Both CCPA doses significantly increased hippocampal AD thresholds in 12-, 15-, 18-, and 60-day-old rats compared to controls. In contrast, the higher dose significantly decreased AD threshold in the 25-day-old rats. The AD durations were significantly shortened in all age groups except for 25-day-old rats where they were significantly prolonged. A1 receptor expression in the hippocampus was highest in 10-day-old rats and subsequently decreased. Significance: The adenosine A1 receptor agonist CCPA exhibited anticonvulsant activity at all developmental stages studied here except for 25-day-old rats. Age-related differences might be due to the development of presynaptic A1 receptors in the hippocampus.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19036003
003      
CZ-PrNML
005      
20191011115242.0
007      
ta
008      
191007s2019 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3389/fphar.2019.00656 $2 doi
035    __
$a (PubMed)31258477
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Fabera, Petr $u Department of Developmental Epileptology, Institute of Physiology, Czech Academy of Sciences, Prague, Czechia. Department of Neurology, Second Faculty of Medicine, Motol University Hospital, Charles University, Prague, Czechia.
245    10
$a Adenosine A1 Receptor Agonist 2-chloro-N6-cyclopentyladenosine and Hippocampal Excitability During Brain Development in Rats / $c P. Fabera, M. Parizkova, L. Uttl, K. Vondrakova, H. Kubova, G. Tsenov, P. Mares,
520    9_
$a Objective: The adenosinergic system may influence excitability in the brain. Endogenous and exogenous adenosine has anticonvulsant activity presumably by activating A1 receptors. Adenosine A1 receptor agonist 2-chloro-N6-cyclopentyladenosine (CCPA) may thus bolster anticonvulsant effects, but its action and the number of A1 receptors at different developmental stages are not known. Methods: Hippocampal epileptic afterdischarges (ADs) were elicited in 12-, 15-, 18-, 25-, 45-, and 60-day-old rats. Stimulation and recording electrodes were implanted into the dorsal hippocampus. The A1 receptor agonist 2-chloro-N6-cyclopentyladenosine (CCPA, 0.5 or 1 mg/kg) was administered intraperitoneally 10 min before the first stimulation. Control animals were injected with saline. All rats were stimulated with a 2-s series of 1-ms biphasic pulses delivered at 60 Hz with increasing stepwise intensity (0.05-0.6 mA). Each age and dose group contained 9-14 animals. The AD thresholds and durations were evaluated, and the A1 receptors were detected in the hippocampus in 7-, 10-, 12-, 15-, 18-, 21-, 25-, 32-, and 52-day-old rats. Results: Both CCPA doses significantly increased hippocampal AD thresholds in 12-, 15-, 18-, and 60-day-old rats compared to controls. In contrast, the higher dose significantly decreased AD threshold in the 25-day-old rats. The AD durations were significantly shortened in all age groups except for 25-day-old rats where they were significantly prolonged. A1 receptor expression in the hippocampus was highest in 10-day-old rats and subsequently decreased. Significance: The adenosine A1 receptor agonist CCPA exhibited anticonvulsant activity at all developmental stages studied here except for 25-day-old rats. Age-related differences might be due to the development of presynaptic A1 receptors in the hippocampus.
655    _2
$a časopisecké články $7 D016428
700    1_
$a Parizkova, Martina $u Department of Developmental Epileptology, Institute of Physiology, Czech Academy of Sciences, Prague, Czechia. Department of Neurology, Second Faculty of Medicine, Motol University Hospital, Charles University, Prague, Czechia.
700    1_
$a Uttl, Libor $u Department of Developmental Epileptology, Institute of Physiology, Czech Academy of Sciences, Prague, Czechia. National Institute of Mental Health, Klecany, Czechia.
700    1_
$a Vondrakova, Katerina $u Department of Developmental Epileptology, Institute of Physiology, Czech Academy of Sciences, Prague, Czechia. National Institute of Mental Health, Klecany, Czechia.
700    1_
$a Kubova, Hana $u Department of Developmental Epileptology, Institute of Physiology, Czech Academy of Sciences, Prague, Czechia.
700    1_
$a Tsenov, Grygoriy $u Department of Developmental Epileptology, Institute of Physiology, Czech Academy of Sciences, Prague, Czechia. Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Verona, Italy.
700    1_
$a Mares, Pavel $u Department of Developmental Epileptology, Institute of Physiology, Czech Academy of Sciences, Prague, Czechia.
773    0_
$w MED00174597 $t Frontiers in pharmacology $x 1663-9812 $g Roč. 10, č. - (2019), s. 656
856    41
$u https://pubmed.ncbi.nlm.nih.gov/31258477 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20191007 $b ABA008
991    __
$a 20191011115703 $b ABA008
999    __
$a ind $b bmc $g 1452663 $s 1074553
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 10 $c - $d 656 $e 20190614 $i 1663-9812 $m Frontiers in pharmacology $n Front Pharmacol $x MED00174597
LZP    __
$a Pubmed-20191007

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...